Company news
Shanghai Junshi Biosciences Co., Ltd. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients
December 4, 2025
Announcement on Result of Shareholding Reduction by Shareholder with Over 5% Shares
December 4, 2025
Indicative Announcement on Change in Equity of Shareholders with Over 5% Shares Reaching 5% Scale
December 3, 2025
Announcement on Using Temporarily Idle Raised Funds for Cash Management
November 27, 2025
Junshi Biosciences Announces Primary Endpoints Met in JS001sc’s Phase 3 Study for the 1ST-line Treatment of NSQ-NSCLC
November 24, 2025
Announcement on Completion of Registration of Initial Grant under 2025 A-share Stock Option Incentive Plan
November 14, 2025
Report for Q3 2025
October 28, 2025
Announcement on Voluntary Disclosure of the Wholly-owned Subsidiary Passing On-site Inspection by FDA
October 22, 2025
Announcement on Convening the Q3 2025 Performance Briefing
October 21, 2025
Junshi Biosciences Announces FDA’s Approval of IND Application for Phase 2/3 Clinical Study of JS207 for the Neoadjuvant Treatment of NSCLC Patients
October 16, 2025
Announcement on Progress in Shareholding Increase by Controlling Shareholder and One of Actual Controller (Chairman) and Completion of Half of the Planned Increase Period
October 10, 2025
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025
September 29, 2025
Board of Supervisors' Remarks on Publicity of and Verification Opinions on List of Incentive Objects Initially Granted under 2025 A-share Stock Option Incentive Plan
September 22, 2025
Announcement on Adding Extraordinary Proposal and Postponement of the 1st Extraordinary General Meeting in 2025
September 15, 2025
Junshi Biosciences Announces the Phase 3 Study of JS005 (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis Met Primary Endpoints
September 7, 2025
Notice on Convening the 1st Extraordinary General Meeting in 2025
September 5, 2025
Announcement on Voluntary Disclosure of Notice of Approval for Drug Clinical Trial Application Obtained by JT118
September 2, 2025
Announcement on Convening the 2025 Semi-annual Performance Briefing
August 29, 2025
Junshi Biosciences Announces 2025 Interim Financial Results and Provides Corporate Updates
August 26, 2025
Junshi Biosciences Announces the Acceptance of the sNDA for Toripalimab as the 1st-line Treatment of HER2-expressing Urothelial Carcinoma
August 8, 2025
Announcement on Listing and Circulation of Shares Exercised in the 3rd Vesting Period of the 2018 Equity Incentive Plan
June 27, 2025
Announcement on Resolution of the 2024 Annual General Meeting
June 20, 2025
Announcement on Voluntary Disclosure of Obtaining Notice on Acceptance of Application for Drug Clinical Trial for JT118
June 11, 2025
Indicative Announcement on Change in Equity of Shareholders with Over 5% Shares Reaching 1%
June 5, 2025
Announcement on Sub-project Change and Amount Adjustment of Some Investment Projects Financed by Raised Funds
May 29, 2025
Junshi Biosciences Announces Ongericimab’s sNDA Approval in China
May 27, 2025
Junshi Biosciences Announces the sNDA Approval of Toripalimab for the 1st-line Treatment of Melanoma
April 25, 2025
Announcement on Share Increase Plan for Controlling Shareholder, One of Actual Controllers and Chairman
April 11, 2025
Junshi Biosciences Announces 2024 Full Year Financial Results and Provides Corporate Updates
March 28, 2025
Announcement on 2024 Annual Profit Distribution Plan
March 27, 2025
Junshi Biosciences Announces Toripalimab’s Approval in Singapore
March 26, 2025
Junshi Biosciences Announces Approval of sNDA for Toripalimab in Combination with Bevacizumab for 1st-line Treatment of Advanced Hepatocellular Carcinoma
March 23, 2025